Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors (NCT06993844)
A Phase 1/2, Open-label, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ETX-636, a Pan-mutant-selective PI3Kฮฑ Inhibitor, as Monotherapy and in Combination With Other Anticancer Therapies in Participants With Advanced Solid Tumors
๐ฉบ Plain-English Summary (8th-Grade Level)
Phase 1/2, open-label study of ETX-636 in participants with advanced solid tumors
Who can join: Review the eligibility criteria below.
Location: Hoag Memorial Hospital Presbyterian โ Newport Beach, California
Age range: 18 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (15 Sites)
- Hoag Memorial Hospital Presbyterian โ Newport Beach, California
- UCSF Helen Diller Family Comprehensive Cancer Center โ San Francisco, California
- Yale University, Yale Cancer Center โ New Haven, Connecticut
- Beth Israel Deaconess Medical Center โ Boston, Massachusetts
- Dana-Farber Cancer Institute โ Boston, Massachusetts
- Carolina BioOncology Institute โ Huntersville, North Carolina
- The University of Texas MD Anderson Cancer Center โ Houston, Texas
- START โ San Antonio, Texas
- NEXT โ Fairfax, Virginia
- Fred Hutchinson Cancer Center โ Seattle, Washington
- Beijing Luhe Hospital,Capital Medical University โ Beijing,
- Fujian Cancer Hospital โ Fuzhou,
- Sun Yat-sen University Cancer Center โ Guangzhou,
- Shandong Cancer Hospital&Institute โ Shandong,
- Fudan University Shanghai Cancer Hospital โ Shanghai,
๐ Contact the Study Coordinator
Phone: (617) 383-4993
Email: janaki.parameswaran@Ensemtx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Solid Tumors
- A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma โ Scottsdale, Arizona
- A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer โ Orange, California
- QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations โ Denver, Colorado
- A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors โ Denver, Colorado
- A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer โ Scottsdale, Arizona
- A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations โ Los Angeles, California
Explore by condition: All Advanced Solid Tumors clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.